Atlas Trials

Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1

Clinical trial NCT05520970 · TERMINATED

Trial details

NCT number
NCT05520970
Sponsor
Cellid Co., Ltd.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
COVID-19Vaccines
Start date
2022-08-19
Primary completion
2022-11-08
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.